Market Cap | 129.73B | P/E | 18.00 | EPS this Y | -89.20% | Ern Qtrly Grth | -19.00% |
Income | -6.54B | Forward P/E | 8.64 | EPS next Y | 819.70% | 50D Avg Chg | -4.00% |
Sales | 46.51B | PEG | -14.47 | EPS past 5Y | 10.73% | 200D Avg Chg | -12.00% |
Dividend | 4.00% | Price/Book | 4.03 | EPS next 5Y | -4.81% | 52W High Chg | -24.00% |
Recommedations | 2.80 | Quick Ratio | 0.94 | Shares Outstanding | 2.03B | 52W Low Chg | 3.00% |
Insider Own | 0.11% | ROA | 6.00% | Shares Float | 2.02B | Beta | 0.46 |
Inst Own | 77.93% | ROE | -26.59% | Shares Shorted/Prior | 21.79M/28.01M | Price | 61.75 |
Gross Margin | 76.18% | Profit Margin | -14.06% | Avg. Volume | 8,754,443 | Target Price | 52.25 |
Oper. Margin | 21.29% | Earnings Date | Oct 31 | Volume | 9,548,659 | Change | 0.36% |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
BMO Capital | Market Perform | Sep 27, 24 |
BMO Capital | Market Perform | Sep 23, 24 |
Cantor Fitzgerald | Neutral | Sep 16, 24 |
Jefferies | Hold | Aug 28, 24 |
Barclays | Underweight | Aug 22, 24 |
TD Cowen | Hold | Aug 12, 24 |
Barclays | Underweight | Jul 29, 24 |
Deutsche Bank | Hold | Jul 23, 24 |
Cantor Fitzgerald | Neutral | Jul 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BOERNER CHRISTOPHER S. | Chief Executive Offi.. Chief Executive Officer | Dec 05 | Buy | 49.78 | 2,000 | 99,560 | 82,672 | 12/07/23 |
BOERNER CHRISTOPHER S. | Chief Executive Offi.. Chief Executive Officer | Nov 28 | Buy | 48.86 | 3,071 | 150,049 | 79,384 | 11/30/23 |
Samuels Theodore R. II | Director Director | Nov 20 | Buy | 49.81 | 8,500 | 423,385 | 35,500 | 11/21/23 |
Powell Ann | EVP, Chief Human Res.. EVP, Chief Human Resources | Aug 24 | Sell | 61.25 | 17,986 | 1,101,642 | 27,868 | 08/28/23 |
Plenge Robert M | EVP, Chief Research.. EVP, Chief Research Officer | Aug 03 | Sell | 61.14 | 732 | 44,754 | 6,584 | 08/07/23 |
VESSEY RUPERT | EVP & President, Res.. EVP & President, Research | May 03 | Sell | 67.06 | 50,385 | 3,378,818 | 47,751 | 05/04/23 |
Caforio Giovanni | Board Chair and CEO Board Chair and CEO | Feb 06 | Sell | 74.65 | 240,000 | 17,916,000 | 236,104 | 02/08/23 |
Powell Ann | EVP, Chief Human Res.. EVP, Chief Human Resources | Feb 06 | Sell | 74.69 | 11,183 | 835,258 | 23,043 | 02/08/23 |
Powell Ann | EVP, Chief Human Res.. EVP, Chief Human Resources | Nov 09 | Sell | 80.45 | 16,250 | 1,307,312 | 34,226 | 11/14/22 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Nov 07 | Option | 54.85 | 52,604 | 2,885,329 | 102,989 | 11/09/22 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Nov 07 | Sell | 78.88 | 45,910 | 3,621,381 | 57,079 | 11/09/22 |
Elkins David V | EVP, Chief Financial.. EVP, Chief Financial Officer | Sep 13 | Sell | 71.32 | 133,951 | 9,553,385 | 119,786 | 09/15/22 |
Elkins David V | EVP, Chief Financial.. EVP, Chief Financial Officer | Sep 13 | Option | 48.49 | 123,277 | 5,977,702 | 223,737 | 09/15/22 |
Powell Ann | EVP, Chief Human Res.. EVP, Chief Human Resources | Sep 14 | Sell | 70.75 | 25,000 | 1,768,750 | 50,476 | 09/15/22 |
Caforio Giovanni | Board Chair and CEO Board Chair and CEO | Jun 13 | Sell | 74.04 | 30,000 | 2,221,200 | 551,104 | 06/14/22 |
LEUNG SANDRA | EVP, General Counsel EVP, General Counsel | Jun 06 | Sell | 74.89 | 65,000 | 4,867,850 | 308,627 | 06/07/22 |
Caforio Giovanni | Board Chair and CEO Board Chair and CEO | Mar 21 | Sell | 71.52 | 25,000 | 1,788,000 | 581,524 | 03/23/22 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Mar 16 | Option | 53.64 | 47,305 | 2,537,440 | 93,613 | 03/18/22 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Mar 16 | Sell | 69.25 | 74,559 | 5,163,211 | 50,385 | 03/18/22 |
Santiago Karen Murphy | SVP & Controller SVP & Controller | Mar 14 | Sell | 69.195 | 6,577 | 455,096 | 16,704 | 03/16/22 |
BOERNER CHRISTOPHER S. | EVP, Chief Commercia.. EVP, Chief Commercial Officer | Mar 14 | Sell | 69.197 | 29,532 | 2,043,526 | 41,966 | 03/16/22 |
Caforio Giovanni | Board Chair and CEO Board Chair and CEO | Feb 24 | Sell | 67 | 30,000 | 2,010,000 | 453,455 | 02/28/22 |
von Autenried Paul | EVP, Chief Informati.. EVP, Chief Information Officer | Nov 22 | Sell | 57.19 | 51,134 | 2,924,353 | 63,536 | 11/24/21 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Nov 23 | Option | 48.03 | 52,213 | 2,507,790 | 98,355 | 11/23/20 |
VESSEY RUPERT | EVP, Research & Earl.. EVP, Research & Early Dev. | Nov 23 | Sell | 61.28 | 57,591 | 3,529,176 | 51,343 | 11/23/20 |